News Focus
News Focus
icon url

unpathedhaunt

01/25/23 8:30 AM

#343513 RE: Protector #343510

"As part of the deal, Oncologie will also enter into an agreement with Avid for future contract development and manufacturing activities in support of bavituximab. Roth Capital Partners acted as financial advisor to Avid in this transaction, rendering a Fairness Opinion to its board of directors."

https://oncxerna.com/avid-bioservices-and-oncologie-enter-into-asset-assignment-and-purchase-agreement-for-avids-ps-targeting-program-including-bavituximab/